李氏大药厂(00950) - 2023 Q1 - 季度业绩

Cessation of Quarterly Financial Results Announcement The company's Board of Directors announced the cessation of proactive quarterly financial results publication, while continuing with interim and annual reports Decision Details The Board of Directors of Lee's Pharmaceutical Holdings Limited announced the cessation of proactive publication of quarterly financial results for the first three and nine months of the current and subsequent financial years, while continuing to publish interim and annual results as per HKEX listing rules - The company will cease to proactively announce and publish quarterly financial results for the first three and nine months of the current and subsequent financial years[1] - The company will continue to announce and publish its interim and annual financial results in accordance with the Listing Rules of The Stock Exchange of Hong Kong Limited[3] Rationale and Impact The Board believes that ceasing quarterly results will reduce company burden, allowing management to focus on core operations, while maintaining shareholder communication and financial transparency without compromising investor interests - Cessation of quarterly financial results publication will reduce the company's time, effort, costs, and administrative burden, allowing management to focus more on the operation and development of the Group's principal businesses[5] - The company will continue to communicate with shareholders and investors in a timely and proactive manner, providing sufficient transparency regarding the Group's financial position[5] - The Board believes that ceasing the publication of quarterly financial results will not sacrifice or prejudice the interests of the company's shareholders and investors[5] Corporate Governance and General Information This announcement, issued by the Board of Lee's Pharmaceutical Holdings Limited, lists the executive, non-executive, and independent non-executive directors as of the announcement date, April 28, 2023 - As of the announcement date, the executive directors are Ms. Lee Siu Fong (Chairman) and Ms. Lee Yuen Yee; the non-executive directors are Dr. Li Xiao Yi and Mr. James Charles Gale; and the independent non-executive directors are Dr. Chan Hau Chong, Mr. Lam Yat Cheong, and Dr. Jim Wah Keung[4] - The announcement date is April 28, 2023[6]